HANGZHOU, China, November 28, 2023- Recently, British Journal of Anasthesia published the pivotal Phase III clinical results of adamgammadex.

This phase III clinical study is a multicentre, randomised, double-blind, positive-controlled, non-inferiority phase III clinical trial compared the efficacy and safety of adamgammadex and sugammadex. 310 subjects were randomized to receive adamgammadex (4 mg/ kg) or sugammadex (2 mg/ kg) at reappearance of the second twitch of the train-of-four (TOF), and results found that adamgammadex had a lower incidence of adverse drug reactions compared with sugammadex (anaphylactic reaction, recurarisation, decreased heart rate, and laryngospasm; P=0.047). The clinical results have demonstrated that adamgammadex was non-inferior to sugammadex with a possible lower incidence of adverse drug reactions compared with sugammadex. Adamgammadex may have a potential advantage in terms of its overall risk-benefit profile.

For more information please refer to:

Yujun Zhang, Yingying Jiang, Qian Lei, Chaoyu Li, Shu’an Jin, Qin Wang, Yidan Huang, Yalan Li, Yi Hong, Shoushi Wang, Han Lin, Hong Li, Yangwen Ou, Xiaohua Zou, Qiang Sun, Qulian Guo, Zhigang Chen, Su Min, Youmao Qi, Qing Jie, Jin Liu, Bin Liu, Wensheng Zhang. Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block，British Journal of Anaesthesia (doi: 10.1016/j.bja.2023.10.022).